What Do They Do for a Blood Clot: Key Treatments

Treatment for a blood clot depends on its location and severity, but the most common first step is anticoagulation, a category of drugs commonly called blood thinners. These medications stop the clot from growing and prevent new ones from forming, giving the body’s own enzymes time to dissolve the existing clot. For more dangerous situations, doctors may use clot-dissolving drugs, catheter-based procedures, or surgery. The treatment path typically begins with confirming the clot exists and gauging how serious it is.

How Doctors Confirm a Clot

Before any treatment starts, doctors need to know whether a clot is actually present and how extensive it is. The process usually combines a clinical scoring tool, a blood test, and imaging. The most widely used scoring system is the Wells score, which assigns points based on factors like recent surgery, limb swelling, active cancer, and immobility. In trauma patients, the Wells score has proven highly accurate at stratifying risk, with the ability to rule out deep vein thrombosis (DVT) in low-risk patients with perfect sensitivity.¹

If the clinical score suggests a clot is possible, the next step is often a D-dimer blood test. D-dimer is a protein fragment released when a blood clot breaks down. A low level makes a clot unlikely, while a high level warrants imaging. D-dimer and compression ultrasound work as complements: D-dimer is mainly used to exclude a clot in certain patients, while ultrasound is used to confirm one.² For suspected pulmonary embolism (PE), where a clot has traveled to the lungs, CT angiography is the standard imaging tool. D-dimer levels also correlate with how large the clot burden is; higher levels are linked to clots in the main pulmonary arteries and more extensive blockage.³

Blood Thinners as the Standard Treatment

For most blood clots, the backbone of treatment is anticoagulation. Blood thinners do not dissolve clots that already exist. Instead, they prevent the clot from enlarging and stop new clots from forming, while the body’s natural fibrinolytic system gradually breaks down the existing clot over weeks to months. The choice of which blood thinner to use has changed dramatically over the past two decades.

Treatment typically begins with a fast-acting injectable anticoagulant or, increasingly, an oral medication that works quickly. The injectable options include unfractionated heparin (UFH), given through an IV in a hospital setting, and low-molecular-weight heparins (LMWH) such as enoxaparin, which are injected under the skin and can sometimes be used at home. Both types work by boosting the activity of antithrombin, an enzyme that neutralizes clotting factors. LMWHs are derived from standard heparin but processed into smaller molecules, giving them more predictable effects and fewer required blood tests.

For longer-term treatment, patients transition to oral anticoagulants. The two main categories are vitamin K antagonists like warfarin and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran. DOACs have largely replaced warfarin as the preferred option for most patients. A large study of extended treatment found that DOACs were associated with about a third lower risk of recurrent clots compared to warfarin, with similar rates of serious bleeding and death.⁴ Even for clots in less common locations like the brain’s venous sinuses, DOACs perform similarly to warfarin in preventing recurrence and achieving reopening of the blocked vessel, while carrying a lower risk of major bleeding.⁵

DOACs also have practical advantages. They do not require routine blood monitoring, and they have far fewer food interactions than warfarin. That said, warfarin remains the appropriate choice in certain situations, including patients with mechanical heart valves or antiphospholipid syndrome.

Reversing Blood Thinners in Emergencies

A key concern with any anticoagulant is what happens if you need emergency surgery or start bleeding uncontrollably. Each class of blood thinner has its own reversal strategy. For heparin, protamine sulfate is the approved antidote. For warfarin, doctors use vitamin K and prothrombin complex concentrates. For DOACs, specific reversal agents now exist: idarucizumab reverses dabigatran, while andexanet alfa targets the factor Xa inhibitors like rivaroxaban and apixaban.⁶

When idarucizumab is given to patients on dabigatran who present with major bleeding, clotting function returns to normal range within about 30 minutes, and the anticoagulant effect stays suppressed for at least 24 hours.⁷ Before these specific antidotes were developed, nonspecific clotting-factor concentrates and recombinant factor VIIa were the fallback options.⁸ The existence of reliable reversal agents has made doctors more comfortable prescribing DOACs, especially for older patients or those with a moderate risk of falling.

Clot-Dissolving Drugs

When a blood clot is causing immediate danger, such as a massive pulmonary embolism, an acute stroke, or a heart attack, doctors may use thrombolytics. These drugs, the most well-known being tissue plasminogen activator (tPA), actively break down the clot rather than simply preventing it from growing. Thrombolytics are far more aggressive than blood thinners and are reserved for emergencies because they carry a real risk of serious bleeding. The problem is that tPA circulates throughout the body and can dissolve clots everywhere, including beneficial ones at wound sites that are keeping you from bleeding.⁹

For stroke, thrombolytics work best when given within a few hours of symptom onset. The treatment window is narrow, which is why “time is brain” became a medical mantra. For pulmonary embolism, systemic thrombolytics are used when the clot is large enough to cause dangerous drops in blood pressure or heart strain. In less immediately life-threatening situations, doctors may opt for a targeted approach instead.

Catheter-Based Procedures and Mechanical Removal

When blood thinners alone are not enough, or when a clot needs to be removed more quickly, interventional procedures offer a middle ground between medication and open surgery. Catheter-directed thrombolysis (CDT) involves threading a thin catheter through the blood vessels to the site of the clot, then infusing a low dose of a clot-dissolving drug directly into the blockage. Because the drug is delivered locally rather than through the whole bloodstream, it uses a fraction of the dose that systemic thrombolysis requires.¹⁰

Newer techniques combine the catheter with mechanical devices that physically break up or suction out the clot. Ultrasound-accelerated catheter-directed thrombolysis, for instance, uses ultrasound energy to help the drug penetrate deeper into the clot. In one series, this approach successfully restored blood flow in the vast majority of treated patients.¹¹ Percutaneous mechanical thrombectomy devices, which physically grab or grind down the clot, report technical success rates of over 80%.¹²

The Society for Vascular Surgery and the American Venous Forum recommend considering early clot-removal strategies in patients who have a large clot in the major veins of the leg and pelvis, especially if symptoms are less than two weeks old. They strongly recommend these interventions when a clot threatens the blood supply to the limb. When thrombolytic drugs are contraindicated, surgical thrombectomy is an alternative.¹³

Inferior Vena Cava Filters

Some patients cannot take blood thinners at all, whether because of active bleeding, recent brain hemorrhage, or upcoming surgery. In those situations, doctors may place a small metal filter inside the inferior vena cava, the large vein that carries blood from the lower body back to the heart. The filter catches clots traveling upward before they can reach the lungs.

IVC filters are not a treatment for the clot itself. They are a physical barrier to prevent pulmonary embolism. In a review of nearly a thousand patients at one academic hospital, the most common reason for filter placement was trauma, followed by cancer and bleeding during anticoagulant therapy.¹⁴ About half of the patients in that study did not even have an active clot at the time; the filter was placed as a preventive measure. These devices are designed to be retrievable once the patient can safely go back on blood thinners, but retrieval rates remain disappointingly low. In the same study, only about one in ten retrievable filters was actually removed. Failed retrieval attempts were caused by the filter becoming embedded in the vessel wall, protruding through the vessel, or catching a clot. Leaving a filter in place long-term carries its own risks, including clotting around the filter and vessel damage.

How Long You Stay on Treatment

The duration of blood thinner therapy depends heavily on what triggered the clot. A clot provoked by a clear, temporary risk factor, such as surgery, a broken leg, or prolonged bed rest, is typically treated for about three months because the risk of recurrence is low once that trigger is gone. A second unprovoked clot, or one associated with active cancer, usually calls for indefinite treatment. The decision gets harder after a first unprovoked clot in a major vein or in the lungs, where the choice between stopping at three months and continuing indefinitely depends on the individual’s bleeding risk.¹⁵

For patients who do continue long-term, there is encouraging evidence that a reduced dose of a DOAC works nearly as well as a full dose while causing less bleeding. A meta-analysis of randomized trials found that reduced-dose DOACs had a comparable risk of recurrent clots, but cut the risk of major or clinically relevant bleeding by about 30%.¹⁶ A separate meta-analysis confirmed this pattern, showing that reduced doses significantly lowered major bleeding risk without increasing clot recurrence or death.¹⁷ This makes reduced-dose therapy an attractive option for patients who need to stay on anticoagulation for months or years, especially those at higher risk of bleeding.

Compression Stockings and Post-Clot Syndrome

After a DVT, many patients are advised to wear graduated compression stockings on the affected leg. The goal is to prevent post-thrombotic syndrome (PTS), a chronic condition marked by leg pain, swelling, skin discoloration, and sometimes ulcers. PTS develops in a significant minority of DVT patients and can persist for years.

The evidence on compression stockings has been debated. A meta-analysis of randomized trials found that wearing elastic compression stockings was associated with a roughly 27% reduction in the overall rate of PTS, though the studies showed considerable variability in their results.¹⁸ A separate trial found that prolonged use of compression stockings after a proximal DVT significantly reduced symptoms, though whether this ultimately prevents the most severe complications like skin ulcers was unclear.¹⁹ Compression stockings are low-risk and inexpensive, so many doctors still recommend them, especially for patients who had a large clot in the upper leg.

Cancer Patients and Blood Clots

Cancer and blood clots are closely linked. Tumors can activate the clotting system, and cancer treatments like chemotherapy and surgery also raise the risk. For decades, LMWH injections were the standard treatment for cancer-associated clots because early oral anticoagulants like warfarin were unreliable in cancer patients due to nausea, drug interactions, and erratic absorption. DOACs have more recently become the preferred option for most cancer patients with clots, offering comparable effectiveness and greater convenience.²⁰

The exception involves gastrointestinal and possibly genitourinary cancers. DOACs have been linked to an increased risk of major bleeding in patients with these tumor types, particularly when there is an intact tumor inside the gut or urinary tract. Guidelines from the National Comprehensive Cancer Network suggest that DOACs are preferred for patients without gastric or gastroesophageal lesions, but that LMWH may be a safer choice when intraluminal tumors are present.²¹ For GI cancer patients specifically, apixaban may be the better-tolerated DOAC if one is used, though caution is still warranted with upper GI or unresected lower GI tumors.²²

Blood Clots During Pregnancy

Pregnancy creates a unique challenge because DOACs and warfarin both cross the placenta and can harm the fetus. This leaves LMWH as the anticoagulant of choice for pregnant patients. Systematic reviews have confirmed that LMWH is both safe and effective for preventing and treating clots during pregnancy, with a lower risk of osteoporosis and other complications compared to unfractionated heparin.²³²⁴ LMWH is injected under the skin, usually once or twice daily, and is managed throughout pregnancy with dose adjustments as the patient’s weight and blood volume change. After delivery, patients can typically transition to an oral anticoagulant if continued treatment is needed.

Preventing Clots in the Hospital

For patients who are bedridden after surgery, a stroke, or a major injury, hospitals use a combination of strategies to prevent clots from forming in the first place. Low-dose anticoagulants are the most common approach, but for patients who cannot take blood thinners, mechanical prevention plays a key role.

Intermittent pneumatic compression (IPC) devices are inflatable sleeves placed around the calves or legs. They periodically squeeze and release, mimicking the pumping action of walking and keeping blood flowing. A large randomized trial in immobile stroke patients found that IPC reduced the risk of DVT by about a third, dropping the rate from roughly 12% in the control group to about 8.5% in the treatment group.²⁵ The same trial suggested a possible improvement in survival as well.²⁶ IPC devices are also commonly used after joint replacement surgery.²⁷

Living on Blood Thinners

If you are on anticoagulants for an extended period, the medication shapes some everyday decisions. This is especially true for warfarin, which has a notoriously narrow window where it works without either leaving you unprotected or making you bleed too easily. A systematic review found that at least 78 herbs, foods, or dietary supplements interact with warfarin, with the majority amplifying its blood-thinning effect.²⁸ Some interactions were linked to serious events, including intracranial bleeding.

The main dietary culprit is vitamin K, found in leafy greens like kale, spinach, and broccoli. Vitamin K directly counteracts warfarin’s mechanism. The advice is not to avoid these foods entirely, but to eat them in consistent amounts so the warfarin dose stays properly calibrated. Patients should also be cautious with supplements of vitamins A, E, and C, and with heavy alcohol use.²⁹

DOACs have fewer food interactions, which is one of the reasons they have largely replaced warfarin for most patients. They are not interaction-free, however. Their blood levels can be affected by drugs that alter certain transport proteins and liver enzymes. Combining any anticoagulant with antiplatelet drugs like aspirin or with nonsteroidal anti-inflammatory drugs like ibuprofen increases bleeding risk, a combination that is sometimes necessary but should always be managed carefully.³⁰

Factor XI Inhibitors and What Comes Next

The holy grail in anticoagulation has always been a drug that prevents harmful clots without increasing the risk of bleeding. Current blood thinners all work by suppressing parts of the clotting system that are also responsible for stopping bleeding when you are injured. That is why every existing anticoagulant carries some bleeding risk.

A new class of drugs targeting factor XI, a clotting protein involved in sustaining and amplifying clots but less critical for initial wound healing, is now in advanced clinical testing. Early studies suggest that factor XI inhibitors can reduce clot formation without meaningfully increasing bleeding, which would be a genuine breakthrough if it holds up in large trials.³¹ The idea is rooted in the observation that people born with low factor XI levels rarely develop dangerous clots but also rarely experience spontaneous bleeding, suggesting this part of the clotting system can be safely turned down.³² Several factor XI inhibitors, both injectable antibodies and oral small molecules, are in phase 2 and phase 3 trials. If they deliver on their promise, they could change the risk calculus for millions of patients who currently live with the trade-off between clot prevention and bleeding risk.